BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 06-Jul-2015

As per Regulation 30 of DSE Listing Regulations, the Company has informed that a meeting of the Board of Directors will be held on July 14, 2015 at 2:00 PM to consider, among others, audited financial statements of the Company for the year ended on March 31, 2015.

SQURPHARMA 01-Feb-2015

(Q3 Un-audited): Consolidated profit after tax (excluding non controlling interest) from Oct'14 to Dec'14 was Tk. 1,527.92 million with consolidated EPS of Tk. 2.76 as against Tk. 1,508.31 million and Tk. 2.72 respectively for the same period of the previous year. Whereas consolidated profit after tax from Apr'14 to Dec'14 was Tk. 4,220.59 million with consolidated EPS of Tk. 7.61 as against Tk. 4,104.82 million and Tk. 7.41 respectively for the same period of the previous year.

SQURPHARMA 27-Nov-2014

Jahanara Chowdhury, one of the Sponsors of the Company, has further reported that she has completed her sale of 4,99,000 shares of the Company at prevailing market price through Stock Exchange as announced earlier.

SQURPHARMA 27-Nov-2014

Jahanara Chowdhury, one of the Sponsors of the Company, has expressed her intention to transfer 27,00,000 shares out of her total holding of 28,00,007 shares of the Company to her daughters namely, Meher Parveen (9,00,000 shares), Shamima Nasreen (9,00,000 shares) and Muniza Karim (9,00,000 shares), by way of gift outside the trading system of the Exchange within next 30 working days from the date of issuance of approval letter by DSE.

SQURPHARMA 02-Nov-2014

(H/Y): As per un-audited half yearly accounts as on 30.09.2014 (April'14 to Sep'14), the Company has reported consolidated net profit after tax (excluding non-controlling interests) of Tk. 2,692.67 million with consolidated EPS of Tk. 4.86 as against Tk. 2,515.49 million and Tk. 4.54 respectively for the same period of the previous year. Whereas consolidated net profit after tax (excluding non-controlling interests) was Tk. 1,303.78 million with consolidated EPS of Tk. 2.35 for the period of 3 months (July'14 to Sep'14) ended on 30.09.2014 as against Tk. 1,183.65 million and Tk. 2.14 respectively for the same period of the previous year.

SQURPHARMA 27-Oct-2014

Jahanara Chowdhury, one of the Sponsors of the Company, has expressed her intention to sell 4,99,000 shares out of her total holding of 32,99,007 shares of the Company at prevailing market price through Stock Exchange (DSE) within next 30 working days.

SQURPHARMA 20-Jul-2014

There will be no price limit on the trading of the shares of the Company today (20.07.2014) following its corporate declaration.

SQURPHARMA 20-Jul-2014

The Board of Directors has recommended 30% cash dividend and 15% stock dividend for the year ended on March 31, 2014. Date of AGM: 25.09.2014, Time: 10:00 AM, Venue: Factory premises, Kaliakoir, Gazipur. Record Date: 26.08.2014. The Company has also reported NAV of Tk. 22,277.52 million, EPS of Tk. 8.36 and NOCFPS of Tk. 12.90 for the year ended on March 31, 2014.

SQURPHARMA 14-Jul-2014

As per Regulation 30 of DSE Listing Regulations, the Company has informed that a meeting of the Board of Directors will be held on July 17, 2014 at 2:30 PM to consider, among others, audited financial statements of the Company for the year ended on March 31, 2014.

SQURPHARMA 02-Feb-2014

(Q3): As per un-audited quarterly accounts for the 3rd quarter ended on 31st December 2013 (Oct'13 to Dec'13), the Company has reported consolidated profit after tax (excluding non controlling interest) of Tk. 1,589.34 million with consolidated EPS of Tk. 3.30 as against Tk. 1,194.34 million and Tk. 2.48 respectively for the same period of the previous year. Whereas consolidated profit after tax (excluding non controlling interest) was Tk. 4,104.82 million with consolidated EPS of Tk. 8.52 for the period of nine months (Apr'13 to Dec'13) ended on 31.12.2013 as against Tk. 3,245.10 million and Tk. 6.73 respectively for the same period of the previous year.

Previous Next page